0 Valutazioni

ID

20091

Descrizione

Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00366418

collegamento

https://clinicaltrials.gov/show/NCT00366418

Keywords

  1. 06/02/17 06/02/17 -
Caricato su

6 febbraio 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :


    Non ci sono commenti

    Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

    Eligibility Chronic Lymphocytic Leukaemia Refractory NCT00366418

    Eligibility Chronic Lymphocytic Leukaemia Refractory NCT00366418

    Criteria
    Descrizione

    Criteria

    patients diagnosed with chronic lymphocytic leukemia
    Descrizione

    Chronic Lymphocytic Leukemia

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0023434
    prior therapy with fludarabine or a fludarabine containing regimen
    Descrizione

    fludarabine | Regimen fludarabine containing

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0059985
    UMLS CUI [2,1]
    C0040808
    UMLS CUI [2,2]
    C0059985
    UMLS CUI [2,3]
    C0332256
    cd20 expression on cll cells
    Descrizione

    CD20 Expression Chronic Lymphocytic Leukemia Cells

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C0054946
    UMLS CUI [1,2]
    C0017262
    UMLS CUI [1,3]
    C0023434
    UMLS CUI [1,4]
    C0007634
    neutrophil count anc greater than 500/mm(3)
    Descrizione

    Absolute neutrophil count

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0948762
    platelet count greater than 30k/mm(3)
    Descrizione

    Platelet Count measurement

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0032181
    age 21-99
    Descrizione

    Age

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0001779
    Exclusion Criteria
    Descrizione

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    bulky lymphadenopathy, defined as greater than 1 lymph node with greater than 5cm in largest diameter
    Descrizione

    Lymphadenopathy Bulky | Lymph nodes Quantity Diameter size

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C0497156
    UMLS CUI [1,2]
    C1511341
    UMLS CUI [2,1]
    C0024204
    UMLS CUI [2,2]
    C1265611
    UMLS CUI [2,3]
    C1301886
    UMLS CUI [2,4]
    C0456389
    evidence for transformation into high grade lymphoma (richter's transformation)
    Descrizione

    Transformation High Grade Lymphoma Evidence of | Richter's syndrome

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C3714584
    UMLS CUI [1,2]
    C0079740
    UMLS CUI [1,3]
    C0332120
    UMLS CUI [2]
    C0349631
    ecog performance 3 or higher
    Descrizione

    ECOG performance status

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C1520224
    other concurrent anticancer therapies
    Descrizione

    cancer treatment

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0920425
    less than 3 months from last systemic therapy for cll
    Descrizione

    systemic therapy Chronic Lymphocytic Leukemia

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C1515119
    UMLS CUI [1,2]
    C0023434
    less than 6 months from last monoclonal antibody therapy
    Descrizione

    Monoclonal Antibody Therapy

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0279694
    more than 10 doses rituximab, within 12 months preceeding protocol enrollment, either as single agent or in a combination chemotherapy regimen
    Descrizione

    rituximab Dose Quantity | rituximab Chemotherapy, multiple agents (combination regimen)

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C0393022
    UMLS CUI [1,2]
    C0178602
    UMLS CUI [1,3]
    C1265611
    UMLS CUI [2,1]
    C0393022
    UMLS CUI [2,2]
    C3846439
    chronic or current clinically significant infection, including hiv positivity or hepatitis c
    Descrizione

    Communicable Disease Clinical Significance | HIV Seropositivity | Hepatitis C

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C0009450
    UMLS CUI [1,2]
    C2826293
    UMLS CUI [2]
    C0019699
    UMLS CUI [3]
    C0019196
    moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient's ability to tolerate protocol therapy
    Descrizione

    Moribund | Liver disease Severe | Kidney Disease Severe | Heart Disease Severe | nervous system disorder Severe | Lung disease Severe | Communicable Disease Severe | Metabolic Disease Severe | Disease Severe Protocol Compliance Unable

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1]
    C0424547
    UMLS CUI [2,1]
    C0023895
    UMLS CUI [2,2]
    C0205082
    UMLS CUI [3,1]
    C0022658
    UMLS CUI [3,2]
    C0205082
    UMLS CUI [4,1]
    C0018799
    UMLS CUI [4,2]
    C0205082
    UMLS CUI [5,1]
    C0027765
    UMLS CUI [5,2]
    C0205082
    UMLS CUI [6,1]
    C0024115
    UMLS CUI [6,2]
    C0205082
    UMLS CUI [7,1]
    C0009450
    UMLS CUI [7,2]
    C0205082
    UMLS CUI [8,1]
    C0025517
    UMLS CUI [8,2]
    C0205082
    UMLS CUI [9,1]
    C0012634
    UMLS CUI [9,2]
    C0205082
    UMLS CUI [9,3]
    C0525058
    UMLS CUI [9,4]
    C1299582
    history of mucocutaneous reactions (paraneoplastic pemphigus, stevens-johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis)
    Descrizione

    Mucous Membrane Reaction | Paraneoplastic pemphigus | Stevens-Johnson Syndrome | Lichenoid Eruptions | Skin Diseases, Vesiculobullous | Toxic Epidermal Necrolysis

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C0026724
    UMLS CUI [1,2]
    C0443286
    UMLS CUI [2]
    C1112570
    UMLS CUI [3]
    C0038325
    UMLS CUI [4]
    C0162848
    UMLS CUI [5]
    C0037275
    UMLS CUI [6]
    C0014518
    known anaphylaxis or ige mediated hypersensitivity to murine proteins or to any component of this product
    Descrizione

    Anaphylaxis Murine protein | IgE-mediated hypersensitivity Murine protein | Anaphylaxis Murine protein Component | IgE-mediated hypersensitivity Murine protein Component

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C0002792
    UMLS CUI [1,2]
    C1699668
    UMLS CUI [2,1]
    C0020523
    UMLS CUI [2,2]
    C1699668
    UMLS CUI [3,1]
    C0002792
    UMLS CUI [3,2]
    C1699668
    UMLS CUI [3,3]
    C1705248
    UMLS CUI [4,1]
    C0020523
    UMLS CUI [4,2]
    C1699668
    UMLS CUI [4,3]
    C1705248
    inability to self inject the study medication or to have it administered by a third person
    Descrizione

    Investigational New Drug Injection Self Unable

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C0013230
    UMLS CUI [1,2]
    C1533685
    UMLS CUI [1,3]
    C0036588
    UMLS CUI [1,4]
    C1299582
    inability to understand the investigational nature of the study ability to provide informed consent
    Descrizione

    Study Protocol Comprehension Unable | Informed Consent

    Tipo di dati

    boolean

    Alias
    UMLS CUI [1,1]
    C2348563
    UMLS CUI [1,2]
    C0162340
    UMLS CUI [1,3]
    C1299582
    UMLS CUI [2]
    C0021430

    Similar models

    Eligibility Chronic Lymphocytic Leukaemia Refractory NCT00366418

    Name
    genere
    Description | Question | Decode (Coded Value)
    Tipo di dati
    Alias
    Item Group
    Chronic Lymphocytic Leukemia
    Item
    patients diagnosed with chronic lymphocytic leukemia
    boolean
    C0023434 (UMLS CUI [1])
    fludarabine | Regimen fludarabine containing
    Item
    prior therapy with fludarabine or a fludarabine containing regimen
    boolean
    C0059985 (UMLS CUI [1])
    C0040808 (UMLS CUI [2,1])
    C0059985 (UMLS CUI [2,2])
    C0332256 (UMLS CUI [2,3])
    CD20 Expression Chronic Lymphocytic Leukemia Cells
    Item
    cd20 expression on cll cells
    boolean
    C0054946 (UMLS CUI [1,1])
    C0017262 (UMLS CUI [1,2])
    C0023434 (UMLS CUI [1,3])
    C0007634 (UMLS CUI [1,4])
    Absolute neutrophil count
    Item
    neutrophil count anc greater than 500/mm(3)
    boolean
    C0948762 (UMLS CUI [1])
    Platelet Count measurement
    Item
    platelet count greater than 30k/mm(3)
    boolean
    C0032181 (UMLS CUI [1])
    Age
    Item
    age 21-99
    boolean
    C0001779 (UMLS CUI [1])
    Item Group
    C0680251 (UMLS CUI)
    Lymphadenopathy Bulky | Lymph nodes Quantity Diameter size
    Item
    bulky lymphadenopathy, defined as greater than 1 lymph node with greater than 5cm in largest diameter
    boolean
    C0497156 (UMLS CUI [1,1])
    C1511341 (UMLS CUI [1,2])
    C0024204 (UMLS CUI [2,1])
    C1265611 (UMLS CUI [2,2])
    C1301886 (UMLS CUI [2,3])
    C0456389 (UMLS CUI [2,4])
    Transformation High Grade Lymphoma Evidence of | Richter's syndrome
    Item
    evidence for transformation into high grade lymphoma (richter's transformation)
    boolean
    C3714584 (UMLS CUI [1,1])
    C0079740 (UMLS CUI [1,2])
    C0332120 (UMLS CUI [1,3])
    C0349631 (UMLS CUI [2])
    ECOG performance status
    Item
    ecog performance 3 or higher
    boolean
    C1520224 (UMLS CUI [1])
    cancer treatment
    Item
    other concurrent anticancer therapies
    boolean
    C0920425 (UMLS CUI [1])
    systemic therapy Chronic Lymphocytic Leukemia
    Item
    less than 3 months from last systemic therapy for cll
    boolean
    C1515119 (UMLS CUI [1,1])
    C0023434 (UMLS CUI [1,2])
    Monoclonal Antibody Therapy
    Item
    less than 6 months from last monoclonal antibody therapy
    boolean
    C0279694 (UMLS CUI [1])
    rituximab Dose Quantity | rituximab Chemotherapy, multiple agents (combination regimen)
    Item
    more than 10 doses rituximab, within 12 months preceeding protocol enrollment, either as single agent or in a combination chemotherapy regimen
    boolean
    C0393022 (UMLS CUI [1,1])
    C0178602 (UMLS CUI [1,2])
    C1265611 (UMLS CUI [1,3])
    C0393022 (UMLS CUI [2,1])
    C3846439 (UMLS CUI [2,2])
    Communicable Disease Clinical Significance | HIV Seropositivity | Hepatitis C
    Item
    chronic or current clinically significant infection, including hiv positivity or hepatitis c
    boolean
    C0009450 (UMLS CUI [1,1])
    C2826293 (UMLS CUI [1,2])
    C0019699 (UMLS CUI [2])
    C0019196 (UMLS CUI [3])
    Moribund | Liver disease Severe | Kidney Disease Severe | Heart Disease Severe | nervous system disorder Severe | Lung disease Severe | Communicable Disease Severe | Metabolic Disease Severe | Disease Severe Protocol Compliance Unable
    Item
    moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient's ability to tolerate protocol therapy
    boolean
    C0424547 (UMLS CUI [1])
    C0023895 (UMLS CUI [2,1])
    C0205082 (UMLS CUI [2,2])
    C0022658 (UMLS CUI [3,1])
    C0205082 (UMLS CUI [3,2])
    C0018799 (UMLS CUI [4,1])
    C0205082 (UMLS CUI [4,2])
    C0027765 (UMLS CUI [5,1])
    C0205082 (UMLS CUI [5,2])
    C0024115 (UMLS CUI [6,1])
    C0205082 (UMLS CUI [6,2])
    C0009450 (UMLS CUI [7,1])
    C0205082 (UMLS CUI [7,2])
    C0025517 (UMLS CUI [8,1])
    C0205082 (UMLS CUI [8,2])
    C0012634 (UMLS CUI [9,1])
    C0205082 (UMLS CUI [9,2])
    C0525058 (UMLS CUI [9,3])
    C1299582 (UMLS CUI [9,4])
    Mucous Membrane Reaction | Paraneoplastic pemphigus | Stevens-Johnson Syndrome | Lichenoid Eruptions | Skin Diseases, Vesiculobullous | Toxic Epidermal Necrolysis
    Item
    history of mucocutaneous reactions (paraneoplastic pemphigus, stevens-johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis)
    boolean
    C0026724 (UMLS CUI [1,1])
    C0443286 (UMLS CUI [1,2])
    C1112570 (UMLS CUI [2])
    C0038325 (UMLS CUI [3])
    C0162848 (UMLS CUI [4])
    C0037275 (UMLS CUI [5])
    C0014518 (UMLS CUI [6])
    Anaphylaxis Murine protein | IgE-mediated hypersensitivity Murine protein | Anaphylaxis Murine protein Component | IgE-mediated hypersensitivity Murine protein Component
    Item
    known anaphylaxis or ige mediated hypersensitivity to murine proteins or to any component of this product
    boolean
    C0002792 (UMLS CUI [1,1])
    C1699668 (UMLS CUI [1,2])
    C0020523 (UMLS CUI [2,1])
    C1699668 (UMLS CUI [2,2])
    C0002792 (UMLS CUI [3,1])
    C1699668 (UMLS CUI [3,2])
    C1705248 (UMLS CUI [3,3])
    C0020523 (UMLS CUI [4,1])
    C1699668 (UMLS CUI [4,2])
    C1705248 (UMLS CUI [4,3])
    Investigational New Drug Injection Self Unable
    Item
    inability to self inject the study medication or to have it administered by a third person
    boolean
    C0013230 (UMLS CUI [1,1])
    C1533685 (UMLS CUI [1,2])
    C0036588 (UMLS CUI [1,3])
    C1299582 (UMLS CUI [1,4])
    Study Protocol Comprehension Unable | Informed Consent
    Item
    inability to understand the investigational nature of the study ability to provide informed consent
    boolean
    C2348563 (UMLS CUI [1,1])
    C0162340 (UMLS CUI [1,2])
    C1299582 (UMLS CUI [1,3])
    C0021430 (UMLS CUI [2])

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial